Studies suggest that the diversity of peripheral blood CD8+ TCRs and dynamic changes in intratumoral TCRs at baseline may serve as effective biomarkers for radiotherapy combined with immunotherapy in ESCC (31). This evidence concerns the gene CD8A and esophageal squamous cell carcinoma.